Pharmacological management of lewy body dementia: A systematic review and meta-analysis

American Journal of Psychiatry

Volumn 172, Issue 8, 2015, Pages 731-742

  Stinton, Chris ^a   McKeith, Ian ^a   Taylor, John Paul ^a   Lafortune, Louise ^a   Mioshi, Eneida ^a   Mak, Elijah ^a   Cambridge, Victoria ^a   Mason, James ^a   Thomas, Alan ^a   O'Brien, John T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARMODAFINIL; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; GABAPENTIN; GALANTAMINE; LEVODOPA; MEMANTINE; MODAFINIL; NOOTROPIC AGENT; OLANZAPINE; PIRACETAM; PLACEBO; QUETIAPINE; RAMELTEON; RISPERIDONE; RIVASTIGMINE; ROTIGOTINE; SELEGILINE; TRAZODONE; UNCLASSIFIED DRUG; YOKUKANSAN; ZONISAMIDE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT;

ANOREXIA; COGNITIVE DEFECT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERSALIVATION; INSOMNIA; META ANALYSIS; NAUSEA; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING; ATTITUDE TO HEALTH; CAREGIVER; LEWY BODY DISEASE; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; CAREGIVERS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LEWY BODY DISEASE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 84938691294     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14121582     Document Type: Review

References (71)

1. Aarsland D, Zaccai J, Brayne C: A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20: 1255-1263
2. Vann Jones SA, O'Brien JT: The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014; 44:673-683
3. Emre M, Aarsland D, Brown R, et al: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707
4. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872
5. Noe E, Marder K, Bell KL, et al: Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov Disord 2004; 19:60-67
6. Downes JJ, Priestley NM, Doran M, et al: Intellectual, mnemonic, and frontal functions in dementiawith Lewy bodies: a comparisonwith early and advanced Parkinson's disease. Behav Neurol 1998; 11:173-183
7. Rolinski M, Fox C, Maidment I, et al: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia, and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3:CD006504
8. Matsunaga S, Kishi T, Iwata N: Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry 2015; 23:373-383
9. WangHF,YuJT,TangSW,et al: Efficacyand safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86:135-143
10. National Institute for Health and Clinical Excellence (NICE), Social Care Institute for Excellence (SCIE): Dementia: Supporting People With Dementia and Their Carers in Health and Social Care (NICE Clinical Guideline 42). London, NICE and SCIE, Nov 2006 (http:// www. scie. org. uk/publications/misc/dementia/dementia-guideline. pdf )
11. Oxford Centre for Evidence-Based Medicine (OCEBM), Levels of Evidence Working Group: Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence (http://www. cebm. net/ocebm-levelsof-evidence/)
12. Thomas BH, Ciliska D, Dobbins M, et al:A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004; 1: 176-184
13. Armijo-Olivo S, Stiles CR, Hagen NA, et al: Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract 2012; 18:12-18
14. Selecting studies and collecting data, in Cochrane Handbook for Systematic Reviews of Interventions, Version 5. 1. 0 (updated March 2011). Edited by Higgins JPT,Green S (www. cochrane-handbook. org)
15. Mori E, Ikeda M, Kosaka K, et al: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012; 72: 41-52
16. Aarsland D, Laake K, Larsen JP, et al: Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-712
17. Dubois B, Tolosa E, Katzenschlager R, et al: Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012; 27:1230-1238
18. Leroi I, Brandt J, Reich SG, et al: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004; 19:1-8
19. Ravina B, Putt M, Siderowf A, et al: Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76:934-939
20. Ikeda M, Mori E, Matsuo K, et al: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 2015; 7:4
21. McKeith I, Del Ser T, Spano P, et al: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebocontrolled international study. Lancet 2000; 356:2031-2036
22. Emre M, Aarsland D, Albanese A, et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518
23. Satoh M, Ishikawa H, Meguro K, et al: Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol 2010; 64:337-344
24. Minett TS, Thomas A, Wilkinson LM, et al: What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18:988-993
25. Edwards K, Royall D, Hershey L, et al: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord 2007; 23:401-405
26. Litvinenko IV, Odinak MM, Mogil'naia VI, et al: [Efficacy and safety of galantamine (Reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial)]. Zh Nevrol Psikhiatr Im S S Korsakova 2007; 107:25-33 (Russian)
27. Emre M, Tsolaki M, BonuccelliU, et al: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977
28. Leroi I, Overshott R, Byrne EJ, et al: Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009; 24:1217-1221
29. Aarsland D, Ballard C, Walker Z, et al: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8:613-618
30. Pilot study of armodafinil in patients with dementia with Lewy bodies. Clinicaltrials. gov identifier: NCT01023672 (http://www. clinicaltrials. gov/ct2/show/NCT01023672)
31. Varanese S, Perfetti B, Gilbert-WolfR, et al:Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. Int J Geriatr Psychiatry 2013; 28:1095-1097
32. Sano M, Stern Y, Marder K, et al: A controlled trial of piracetam in intellectually impaired patientswith Parkinson's disease. Mov Disord 1990; 5:230-234
33. Bonelli SB, Ransmayr G, SteffelbauerM,et al: L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004; 63:376-378
34. Goldman JG, Goetz CG, Brandabur M, et al: Effects of dopaminergic medications on psychosis and motor function in dementiawithLewy bodies. Mov Disord 2008; 23:2248-2250
35. Onofrj M, Varanese S, Bonanni L, et al: Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. J Neurol 2013; 260:1731-1742
36. Molloy S, McKeith IG, O'Brien JT, et al: The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005; 76:1200-1203
37. Tse W, Frisina PG, Hälbig TD, et al: The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J Am Med Dir Assoc 2008; 9:670-675
38. Yablonskaya AY, Fedorova NV, Belgusheva ME: Effects of amantadine sulfate on cognitive impairments in patients with Parkinson's disease. Neurosci Behav Physiol 2011; 41:567-573
39. Strothjohann MH, Fuchs GA: Rotigotine and demented Parkinson's disease patients: a therapeutic option. Presented at the Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders, Toronto, June 5-9, 2011
40. Fanciulli A, Assogna F, Caltagirone C, et al: Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia. Aging Clin Exp Res 2013; 25:601-603
41. Portin R, Rinne UK: The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol Scand Suppl 1983; 95:135-144
42. Lee HB, Hanner JA, Yokley JL, et al: Clozapine for treatmentresistant agitation in dementia. J Geriatr Psychiatry Neurol 2007; 20:178-182
43. Cummings JL, Street J, Masterman D, et al: Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13:67-73
44. Moretti R, Torre P, Antonello RM, et al: Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003; 18:205-214
45. Walker Z, Grace J, Overshot R, et al: Olanzapine in dementia with Lewybodies: a clinical study. Int JGeriatrPsychiatry 1999; 14:459-466
46. Marsh L, Lyketsos C, Reich SG: Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001; 42:477-481
47. Takahashi H, Yoshida K, Sugita T, et al: Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:549-553
48. Prohorov T, Klein C, Miniovitz A, et al: The effect of quetiapine in psychotic Parkinsonian patients with and without dementia: an open-labeled study utilizing a structured interview. J Neurol 2006; 253:171-175
49. Kurlan R, Cummings J, Raman R, et al: Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68:1356-1363
50. Workman RHJr, Orengo CA, Bakey AA, et al: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9:594-597
51. Culo S, Mulsant BH, Rosen J, et al: Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled trial. Alzheimer Dis Assoc Disord 2010; 24:360-364
52. Vasile D, Vasiliu O, Vasile ML, et al: The efficacy of psychopharmacologic treatment in depressive disorders associated with Parkinson's disease dementia. Presented at the 18th European Congress of Psychiatry, Munich, Feb 27 to March 2, 2010
53. Massironi G, Galluzzi S, Frisoni GB: Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr 2003; 15:377-383
54. Kasanuki K, Iseki E, Nishida Y, et al: Effectiveness of ramelteon for treatment of visual hallucinations in dementia with Lewy bodies: a report of 4 cases. J Clin Psychopharmacol 2013; 33: 581-583
55. Fujishiro H: Effects of gabapentin enacarbil on restless legs syndrome and leg pain in dementia with Lewy bodies. Psychogeriatrics 2014; 14:132-134
56. Hawkins JW, Tinklenberg JR, Sheikh JI, et al: A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am J Geriatr Psychiatry 2000; 8:221-225
57. Odawara T, Shiozaki K, Togo T, et al: Administration of zonisamide in three cases of dementia with Lewy bodies. Psychiatry Clin Neurosci 2010; 64:327-329
58. Tombini M, Pellegrino G, Di Pino G, et al: Zonisamide for seizures in Parkinson's disease with dementia. Seizure 2013; 22:324-325
59. Mizukami K, Asada T, Kinoshita T, et al: A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol 2009; 12:191-199
60. Kawanabe T, Yoritaka A, Shimura H, et al: Successful treatment with yokukansan for behavioral and psychological symptoms of Parkinsonian dementia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 284-287
61. Gustavsson A, Van Der Putt R, Jönsson L, et al: Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and dementia with Lewy bodies. Int J Geriatr Psychiatry 2009; 24:1072-1078
62. Willan AR, Goeree R, Pullenayegum EM, et al: Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. Pharmacoeconomics 2006; 24:93-106
63. Larsson V, Aarsland D, Ballard C, et al: The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 2010; 25:1030-1038
64. Larsson V, Engedal K, Aarsland D, et al: Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2011; 32:227-234
65. Leroi I, Atkinson R, Overshott R: Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2014; 29:899-905
66. Wesnes K, Aarsland D, Ballard C, et al: Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30:46-54
67. McKeith IG, Wesnes KA, Perry E, et al: Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr Cogn Disord 2004; 18:94-100
68. Burn D, Emre M, McKeith I, et al: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006; 21:1899-1907
69. Barone P, Burn DJ, van Laar T, et al: Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008; 23:1532-1540
70. Thomas AJ, Burn DJ, Rowan EN, et al: A comparison of the efficacy of donepezil in Parkinson's disease with dementiaand dementiawith Lewy bodies. Int J Geriatr Psychiatry 2005; 20:938-944
71. Connolly BS, Lang AE: Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670-1683